# Zylox-Tonbridge Delivers Strong First-Half 2026 Results as International Revenue Surges 349%

- Link: https://www.thailand-business-news.com/pr-news/zylox-tonbridge-delivers-strong-first-half-2026-results-as-international-revenue-surges-349
- Published: 2026-08-20T22:10:00+07:00
- Author: PR Newswire

|   |

_Revenue rose 31.1% to RMB 632 million, while net profit increased 47.8% to RMB 
179 million_

HANGZHOU, China, Aug. 20, 2026 /PRNewswire/ — Zylox-Tonbridge Medical Technology
Co., Ltd. (HKEX: 2190, "Zylox-Tonbridge" or the "Company") today announced its interim
results for the six months ended June 30, 2026.

In the first half of 2026, revenue increased 31.1% year over year to RMB 632 million,
while net profit rose 47.8% to RMB 179 million. Gross profit margin and net profit
margin were 73.4% and 28.3%, respectively. Both improved year over year, reflecting
the Company’s stronger profitability.

During the reporting period, Zylox-Tonbridge’s domestic business maintained steady
growth and continued to gain market share, while international revenue increased
349.3% year over year to RMB 70.64 million, accounting for 11.2% of total revenue.

In April, the Company completed the acquisition of a 60% equity interest in optimed,
a German medical technology company, strengthening its R&D, manufacturing and commercialization
capabilities in Europe. The rapid integration of the two companies’ market access
and commercial resources has supported the commercialization of Zylox-Tonbridge’s
products across 70 countries and regions, as well as the establishment of direct
sales networks in Germany, France and Austria.

**International Business Growth Accelerates**

Zylox-Tonbridge’s products are now commercialized in 70 countries and regions, while
its distribution network covers more than 135 countries and regions. EMEA accounted
for 76% of international revenue, making it a key pillar of the Company’s global
business.

During the period, Zylox-Tonbridge and optimed combined their sales and marketing
teams into a unified global organization and deepened collaboration in supply-chain
management, stent-manufacturing automation and phased logistics planning. This brings
together optimed’s precision-engineering expertise with Zylox-Tonbridge’s operational
and supply-chain capabilities.

In Europe, the Company accelerated channel integration, strengthened local commercialization
and expanded direct sales. It now reaches more than 80% of group purchasing organizations
in Germany and France. The Company also integrated channel resources and advanced
dual-brand expansion across multiple European markets. In July 2026, it secured 
its first direct sales orders in Germany and France, further advancing local operations.

Across Latin America and Asia-Pacific, the Company continued to strengthen its channel
network and made further progress in clinical adoption. Key products, including 
the Zynlastic™ Peripheral Venous Stent System and ZYLOX Unicorn™ Vascular Closure
System, were used for the first time in clinical procedures in markets including
Brazil and South Korea.

**Core Products Sustain Growth as Innovation Pipeline Advances**

During the first half of 2026, Zylox-Tonbridge received NMPA approval for 11 additional
products in China, further expanding its portfolio of neurovascular and peripheral
vascular interventional medical devices. Supported by its expanded portfolio and
strong performance in volume-based procurement tenders and renewals, the Company’s
domestic business maintained steady growth.

In neurovascular intervention, key established products, including the Kylin™ Flow
Diverter and SilverSnake™ Intracranial Intermediate Catheter Series, delivered substantial
revenue growth during the reporting period. The Falco™ Embolization Assist Stent,
approved in 2025, began contributing revenue. The Company also advanced the development
of its Intracranial OCT System, Liquid Embolic System and Self-expandable Aneurysm
Embolization Device.

In peripheral vascular intervention, Zylox-Tonbridge further developed its hemodialysis
access maintenance portfolio, including the ZYLOX KINGKONG™ Peripheral High-Pressure
Balloon Catheter, ZYLOX Transformer™ Peripheral Scoring Catheter and ZENFLOW™ Pufferfish
Scoring Balloon Catheter. It also advanced the ZYLOX Torpedon™ Peripheral Intravascular
Lithotripsy (IVL) System for complex calcified lesions in the lower extremity arteries.

To date, 10 Zylox-Tonbridge products have been accepted into the NMPA’s Special 
Review Procedure for Innovative Medical Devices. Additions since 2025 include the
Self-expandable Aneurysm Embolization Device and ZYLOX Orca™ Balloon Expandable 
Covered Stent, which are expected to further differentiate the Company’s portfolio
and strengthen its competitive position.

Looking forward, Zylox-Tonbridge will continue to pursue innovation and global expansion,
strengthen collaboration across R&D, manufacturing and commercialization, and provide
physicians and patients worldwide with a broader range of high-quality, affordable
products and solutions.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Zylox-Tonbridge Delivers Strong First-Half 2026 Results as International Revenue Surges 349% ](http://www.prnasia.com/story/archive/5030610_CN30610_0?rand=184833)
